CureVac Stock Ceases Trading Following BioNTech Acquisition
Published on 01/21/2026 at 15:11 | Redaktion boerse-global.de
The CureVac share has officially been delisted from public markets, marking the conclusion of its independent trading history. This final step comes after BioNTech successfully completed its full acquisition of the company. A critical deadline now approaches for former minority shareholders seeking to reclaim Dutch withholding tax.
BioNTech finalized the post-offer restructuring on January 6, 2026, merging CureVac N.V. into CureVac Merger B.V. This gave BioNTech complete ownership of all operational activities. Subsequently, the formal delisting from the Nasdaq exchange occurred on January 16, 2026, ending all public trading.
Key transaction details include:
* Total Consideration: Approximately $1.25 billion, paid in BioNTech shares
* Tender Acceptance: 86.75% of CureVac shares Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
